F.D.A. Approves GHB, a ‘Date Rape’ Drug, for Rare Sleeping Disorder

Jazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar.Jazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar.Drugs (Pharmaceuticals), Sedatives, Narcolepsy, Sleep, Food and Drug Administration, Jazz Pharmaceuticals Inc, Drug Abuse and TrafficRead More